tiprankstipranks
Trending News
More News >

Bioventus Holds Annual Meeting, Elects Directors

Story Highlights
Bioventus Holds Annual Meeting, Elects Directors

Don’t Miss TipRanks’ Half-Year Sale

Bioventus ( (BVS) ) has issued an update.

On June 3, 2025, Bioventus, Inc. held its Annual Meeting of Stockholders, where approximately 89.76% of the outstanding shares were represented. During the meeting, stockholders elected Class I directors to the Board and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (BVS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Bioventus stock, see the BVS Stock Forecast page.

Spark’s Take on BVS Stock

According to Spark, TipRanks’ AI Analyst, BVS is a Neutral.

Bioventus’s overall score reflects its current financial struggles, with significant leverage and declining revenues posing risks. While the earnings call offers some optimism for future growth, the technical indicators and valuation concerns weigh heavily on the stock’s outlook.

To see Spark’s full report on BVS stock, click here.

More about Bioventus

Bioventus, Inc. operates in the medical technology industry, focusing on developing and commercializing clinically proven treatments that help people heal quickly and safely. The company primarily offers products in orthobiologics, active healing therapies, and surgical solutions, with a market focus on enhancing the lives of patients worldwide.

Average Trading Volume: 426,953

Technical Sentiment Signal: Sell

Current Market Cap: $529M

Learn more about BVS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1